Evidence map›Paper›PMID 30976412›Full record

ArticleClinical kidney journal2019

Wearable artificial kidney and wearable ultrafiltration device vascular access-future directions.

Ana Coutinho Castro, Mauro Neri, Akash Nayak Karopadi, Anna Lorenzin, Nicola Marchionna, Claudio Ronco

Open access · goldAbstract read
In one paragraph

Article in Clinical kidney journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. From Home to Wearable Hemodialysis: Barriers, Progress, and Opportunities.Clinical journal of the American Society of Nephrology : CJASN · 2024
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. The future of the artificial kidney.Indian journal of urology : IJU : journal of the Urological Society of India
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Ana Coutinho CastroDepartment of Nephrology, Dialysis and Transplantation, Centro Hospitalar do Porto, Porto, Portugal.
Mauro NeriInternational Renal Research Institute of Vicenza (IRRIV), Vicenza, Italy.
Akash Nayak KaropadiInternational Renal Research Institute of Vicenza (IRRIV), Vicenza, Italy.
Anna LorenzinInternational Renal Research Institute of Vicenza (IRRIV), Vicenza, Italy.
Nicola MarchionnaInternational Renal Research Institute of Vicenza (IRRIV), Vicenza, Italy.
Claudio RoncoInternational Renal Research Institute of Vicenza (IRRIV), Vicenza, Italy.
International Renal Research Institute of Vicenza · ITUniversidade do Porto · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSince 2005, three human clinical trials have been performed with the Wearable Artificial Kidney (WAK) and Wearable Ultrafiltration (WUF) device. The lack of an adequate vascular access (VA) has been pointed out as the main limitation to their implementation. Based on the current level of understanding, we will make the first conceptual proposal of an adequate VA suitable for the WAK and the WUF.

methodsAll the literature related to WAK and WUF was reviewed. Based on eight main publications the VA major characteristics were defined: a mean blood flow of 100 mL/min; the capability to allow prolonged and frequent dialysis treatments, without interfering in activities of daily living (ADL); safe and convenient connection/disconnection systems; reduced risk of biofilm formation and coagulation; high biocompatibility. A research was done in order to answer to each necessary technological prerequisites.

resultsThe use of a device similar to a CVC with a 5Fr lumen, seems to be the most feasible option. Totally subcutaneous port devices, like the LifeSite(R) or Dialock (R) systems can be a solution to allow WAK or WUF to operate continuously while patients carry out their ADL. Recently, macromolecules that reduce the risk of thrombosis and infection and are integrated into a CVC have been developed and have the capability of overcoming these major limitations.

conclusionWith an adequate VA, portable HD devices can be acceptable options to address several unmet clinical needs of HD patients.

Indexed as

end-stage renal diseaserenal replacement therapyvascular accesswearable artificial kidneywearable ultrafiltration device

Identifiers

PMID30976412
PMCPMC6452182
OpenAlexW2890864476

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.